Antinociceptive effect of three common analgesic drugs on peripheral neuropathy induced by paclitaxel in rats

David Pascual1, Carlos Goicoechea, Elisa Burgos

  • 1Departamento de Farmacología y Nutrición, Facultad de Ciencias de la Salud, Universidad Rey Juan Carlos, Avda. Atenas s/n, Alcorcón, Madrid, 28922, Spain. david.pascual@urjc.es

Insights

Paclitaxel-induced neuropathic pain can be managed by targeting opioid and NMDA receptors. Morphine and methadone activate opioid receptors, while ketamine blocks NMDA receptors, offering pain relief.

Area of Science:

  • Neuroscience
  • Pharmacology
  • Pain Management

Background:

  • Paclitaxel is a widely used chemotherapy drug.
  • Neuropathic pain is a common and debilitating side effect of paclitaxel treatment.
  • Currently, no validated drugs effectively manage paclitaxel-induced neuropathic pain.

Purpose of the Study:

  • To investigate the role of opioid and NMDA receptors in paclitaxel-induced neuropathic pain.
  • To evaluate the efficacy of morphine, ketamine, and methadone in managing this pain model.

Main Methods:

  • Paclitaxel was administered intraperitoneally to animals on alternate days.
  • Neuropathic pain was assessed by mechanical and thermal withdrawal thresholds.
  • The effects of morphine, ketamine, and methadone, alone and in combination, were evaluated.
  • The involvement of opioid receptors was confirmed using naloxone.

Main Results:

  • Morphine and methadone demonstrated dose-dependent analgesic effects, blocked by naloxone, confirming opioid receptor involvement.
  • Ketamine showed antinociceptive effects at a high dose (50mg/kg) but caused motor impairment.
  • Subanalgesic doses of morphine and ketamine had an additive effect on heat hyperalgesia, but not tactile allodynia.

Conclusions:

  • Opioid receptor activation effectively produces analgesia in paclitaxel-induced neuropathic pain.
  • NMDA receptor blockade with ketamine provides antinociception, particularly at higher doses, though motor impairments are a concern.
  • Low-dose ketamine can enhance the analgesic effects of opioids, suggesting a synergistic therapeutic potential.